Edition:
India

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.30USD
24 Nov 2017
Change (% chg)

$-0.06 (-1.79%)
Prev Close
$3.36
Open
$3.35
Day's High
$3.35
Day's Low
$3.29
Volume
107,567
Avg. Vol
315,836
52-wk High
$4.47
52-wk Low
$2.81

Latest Key Developments (Source: Significant Developments)

Amarin reports Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Amarin :Amarin reports third quarter 2017 financial results and provides update on operations.Q3 loss per share $0.04.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Amarin Corporation Plc - Qtrly net product revenue $47.1 million versus $32.4 million​.  Full Article

Amarin names Mark Salyer chief commercial officer
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Amarin Corporation Plc :Amarin appoints Mark W. Salyer to new position of chief commercial officer.Amarin remains on track to reach record product revenues of $165 to $175 million in 2017​.Most recently, Salyer was at Teva Pharmaceuticals as executive vice president and general manager of Teva Respiratory LLC​.  Full Article

Amarin Corp prices public offering at $2.85 per ADS
Thursday, 11 Aug 2016 

Amarin Corporation Plc : Amarin prices public offering of american depositary shares . Pricing of underwritten public offering of 21.1 million American depositary shares at a price to public of $2.85 per ADS .Sees using net proceeds from offering to advance its reduce-it cardiovascular outcomes trial.  Full Article

Amarin Q2 loss per share $0.07
Thursday, 4 Aug 2016 

Amarin Corporation Plc : Q2 loss per share $0.07 . Amarin reports second quarter 2016 financial results and provides update on operations . Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.13, revenue view $30.0 million -- Thomson Reuters I/B/E/S . Qtrly net total revenue $33.1 million versus $17.7 million .Q2 adjusted non-gaap loss per share $0.09 excluding items.  Full Article

Amarin says FDA to amend SPA agreement for cardiovascular outcomes study
Thursday, 4 Aug 2016 

Amarin Corporation Plc : Amarin and FDA reaffirm concurrence on REDUCE-IT through special protocol assessment agreement amendment . Continues to expect that DMC's 60%, 80% interim analyses will each result in a recommendation to continue reduce-it study as planned . Amendment does not change primary endpoint or overall size of reduce-it study or company's prior guidance on timing . Final efficacy analysis anticipated in 2018 .Secondary and tertiary endpoints of reduce-it study expanded.  Full Article

Amarin appoints Michael Kalb chief financial officer
Thursday, 30 Jun 2016 

Amarin Corporation Plc : Amarin appoints Michael Kalb chief financial officer .Kalb joins Amarin from Taro Pharmaceutical Industries Ltd.  Full Article

BRIEF-Amarin reports Q3 loss per share $0.04

* Amarin reports third quarter 2017 financial results and provides update on operations